Is Time-Limited Therapy the Future for CLL? | Romain Guieze, MD

Checkpoint Inhibitors Show High Response in Hard-to-Treat Lymphoma | Vincent Camus, MD, PhD

Sonrotoclax Could Be a Game‑Changer for MCL? | Amit Agarwal, MD, PhD

Is Rocbrutinib a New Option for CLL Patients? Phase 1 Trial Updates | Jennifer Woyach, MD

Is Rocbrutinib a New Option for CLL Patients? Phase 1 Trial Updates | Jennifer Woyach, MD

Is 1-Year Therapy Just as Effective as Multiple Years? | Othman Al-Sawaf, MD

Is 1-Year Therapy Just as Effective as Multiple Years? | Othman Al-Sawaf, MD

New Drug Combo for B-Cell Lymphoma: How Effective Is It? | Babis Andreadis, MD

CAR-T Cell Therapy: What Lymphoma Patients Need to Know | Fabio Efficace, PhD

Mosunetuzumab: A Potential Option for Frail DLBCL Patients | Jeff Sharman, MD

Mosunetuzumab: A Potential Option for Frail DLBCL Patients | Jeff Sharman, MD

How Venetoclax Combination is Changing MDS/CMML Treatment | Alex Bataller, MD

How Venetoclax Combination is Changing MDS/CMML Treatment | Alex Bataller, MD

How Venetoclax Combination is Changing MDS/CMML Treatment | Alex Bataller, MD

Remote Patient Monitoring for Outpatient Bispecific Therapy in Myeloma | Sridevi Rajeeve, MD

Remote Patient Monitoring for Outpatient Bispecific Therapy in Myeloma | Sridevi Rajeeve, MD

Arlo-Cel - GPRC5D CAR-T: High Response Rates in Heavily Pretreated Myeloma | Susan Bal, MD

Arlo-Cel - GPRC5D CAR-T: High Response Rates in Heavily Pretreated Myeloma | Susan Bal, MD

AURIGA Study Update on MRD Negativity Rates - (D-VRd in NDMM) | Alfred Chung, MD

AURIGA Study Update on MRD Negativity Rates - (D-VRd in NDMM) | Alfred Chung, MD

Predicting Myeloma CAR-T Side Effects Before They Happen | Julia Noll, PhD

Predicting Myeloma CAR-T Side Effects Before They Happen | Julia Noll, PhD

Finding Hidden Myeloma Using IMMunoPET Imaging Technology | Ola Landgren, MD, PhD